ATE548367T1 - Dibenzoäb,füä1,4üoxazapinverbindungen - Google Patents
Dibenzoäb,füä1,4üoxazapinverbindungenInfo
- Publication number
- ATE548367T1 ATE548367T1 AT08732129T AT08732129T ATE548367T1 AT E548367 T1 ATE548367 T1 AT E548367T1 AT 08732129 T AT08732129 T AT 08732129T AT 08732129 T AT08732129 T AT 08732129T AT E548367 T1 ATE548367 T1 AT E548367T1
- Authority
- AT
- Austria
- Prior art keywords
- compounds
- schizophrenia
- depression
- psychotic
- disorders
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89504607P | 2007-03-15 | 2007-03-15 | |
| PCT/US2008/056866 WO2008112900A1 (en) | 2007-03-15 | 2008-03-13 | Dibenzo[b,f][1,4]oxazapine compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE548367T1 true ATE548367T1 (de) | 2012-03-15 |
Family
ID=39472572
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT08732129T ATE548367T1 (de) | 2007-03-15 | 2008-03-13 | Dibenzoäb,füä1,4üoxazapinverbindungen |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US8093237B2 (de) |
| EP (1) | EP2137180B1 (de) |
| JP (1) | JP5421787B2 (de) |
| KR (1) | KR101521951B1 (de) |
| CN (2) | CN101641350B (de) |
| AT (1) | ATE548367T1 (de) |
| AU (1) | AU2008225014B2 (de) |
| BR (1) | BRPI0808828A8 (de) |
| CA (1) | CA2678897C (de) |
| DK (1) | DK2137180T3 (de) |
| ES (1) | ES2384036T3 (de) |
| IL (1) | IL200250A (de) |
| MX (1) | MX2009009535A (de) |
| RU (1) | RU2469033C2 (de) |
| TW (1) | TWI421079B (de) |
| WO (1) | WO2008112900A1 (de) |
| ZA (1) | ZA200906573B (de) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2729474T3 (en) * | 2011-07-08 | 2018-05-22 | Lilly Co Eli | (THIENO [2,3-b] [1,5] BENZOXAZEPIN-4-YL) PIPERAZIN-1-YL COMPOUNDS AS H1-INVERSE AGONISTS / 5-HT2A DOUBLE EFFECTS |
| CN106749219A (zh) * | 2015-11-20 | 2017-05-31 | 江苏恩华药业股份有限公司 | 一种内酰胺类衍生物及其应用 |
| WO2019173761A1 (en) | 2018-03-09 | 2019-09-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | C-abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same |
| WO2023064768A1 (en) * | 2021-10-11 | 2023-04-20 | Baylor College Of Medicine | G-protein-coupled receptor regulators and methods of use thereof |
| TWI820605B (zh) * | 2022-02-18 | 2023-11-01 | 國立臺灣大學 | 抗菌化合物、其製備方法及其用途 |
| CN117164526A (zh) * | 2022-05-27 | 2023-12-05 | 苏州泽璟生物制药股份有限公司 | 2-(哌嗪-2-基)乙腈类衍生物及其制备方法和应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA979441A (en) * | 1967-02-27 | 1975-12-09 | American Cyanamid Company | 11-(piperazinyl) dibenz (b,f) (1,4) oxazepines and analogous thiazepines |
| US3683084A (en) * | 1969-02-06 | 1972-08-08 | Jean Schmutz | Basically substituted heterocycles as anti-emetics |
| DE4127849A1 (de) * | 1991-08-22 | 1993-02-25 | Merck Patent Gmbh | Benzodioxanderivate |
| US5602124A (en) * | 1994-12-12 | 1997-02-11 | Allelix Biopharmaceuticals, Inc. | 5-HT2 receptor ligands |
| IL117798A (en) * | 1995-04-07 | 2001-11-25 | Schering Plough Corp | Tricyclic compounds useful for inhibiting the function of protein - G and for the treatment of malignant diseases, and pharmaceutical preparations containing them |
| JPH0940662A (ja) * | 1995-05-24 | 1997-02-10 | Kyowa Hakko Kogyo Co Ltd | 三環式化合物 |
| JP2005533009A (ja) | 2002-03-28 | 2005-11-04 | イーライ・リリー・アンド・カンパニー | ピペラジン置換されたアリールベンゾジアゼピン類およびそのドーパミン受容体アンタゴニストとしての精神病性障害の処置のための使用 |
| WO2004014895A1 (en) | 2002-08-05 | 2004-02-19 | Eli Lilly And Company | Piperazine substituted aryl benzodiazepines |
| AU2003290079A1 (en) * | 2002-12-20 | 2004-07-14 | Basf Aktiengesellschaft | Pesticidal dibenzo(hetero)azepine derivatives |
| JP2007505106A (ja) * | 2003-09-09 | 2007-03-08 | イーライ リリー アンド カンパニー | アゼピン、オキサゼピン、およびチアゼピンの置換ピペラジン |
| KR101157881B1 (ko) * | 2003-12-22 | 2012-07-06 | 아카디아 파마슈티칼스 인코포레이티드 | 무스카린 작용제로서의 아미노 치환된 디아릴［ａ,ｄ］사이클로헵텐 유사체, 및 신경정신 질환의 치료 방법 |
| DK1804804T3 (da) * | 2004-09-21 | 2012-02-20 | Hypnion Inc | 3-[4-(dibenzo[b,f][1,4]oxazepin-11-yl)-piperazin-1-yl]-2,2-dimethylpropansyre til anvendelse ved behandlingen af søvnforstyrrelser |
-
2008
- 2008-03-13 AT AT08732129T patent/ATE548367T1/de active
- 2008-03-13 KR KR1020097021464A patent/KR101521951B1/ko not_active IP Right Cessation
- 2008-03-13 CN CN2008800085093A patent/CN101641350B/zh not_active Expired - Fee Related
- 2008-03-13 EP EP08732129A patent/EP2137180B1/de not_active Not-in-force
- 2008-03-13 AU AU2008225014A patent/AU2008225014B2/en not_active Ceased
- 2008-03-13 JP JP2009553781A patent/JP5421787B2/ja not_active Expired - Fee Related
- 2008-03-13 BR BRPI0808828A patent/BRPI0808828A8/pt not_active IP Right Cessation
- 2008-03-13 MX MX2009009535A patent/MX2009009535A/es active IP Right Grant
- 2008-03-13 ES ES08732129T patent/ES2384036T3/es active Active
- 2008-03-13 WO PCT/US2008/056866 patent/WO2008112900A1/en active Application Filing
- 2008-03-13 US US12/047,858 patent/US8093237B2/en not_active Expired - Fee Related
- 2008-03-13 CN CN2012103913667A patent/CN103214473A/zh active Pending
- 2008-03-13 DK DK08732129.5T patent/DK2137180T3/da active
- 2008-03-13 CA CA2678897A patent/CA2678897C/en not_active Expired - Fee Related
- 2008-03-13 RU RU2009138039/04A patent/RU2469033C2/ru not_active IP Right Cessation
- 2008-03-14 TW TW097109258A patent/TWI421079B/zh not_active IP Right Cessation
-
2009
- 2009-08-05 IL IL200250A patent/IL200250A/en not_active IP Right Cessation
- 2009-09-21 ZA ZA2009/06573A patent/ZA200906573B/en unknown
-
2011
- 2011-12-12 US US13/323,183 patent/US20120178738A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US8093237B2 (en) | 2012-01-10 |
| ES2384036T9 (es) | 2013-10-14 |
| EP2137180B1 (de) | 2012-03-07 |
| RU2469033C2 (ru) | 2012-12-10 |
| AU2008225014B2 (en) | 2014-12-11 |
| CA2678897C (en) | 2015-10-20 |
| KR101521951B1 (ko) | 2015-05-20 |
| JP2010521486A (ja) | 2010-06-24 |
| CN101641350B (zh) | 2012-11-28 |
| TWI421079B (zh) | 2014-01-01 |
| BRPI0808828A8 (pt) | 2017-11-28 |
| AU2008225014A1 (en) | 2008-09-18 |
| EP2137180A1 (de) | 2009-12-30 |
| CA2678897A1 (en) | 2008-09-18 |
| DK2137180T3 (da) | 2012-07-02 |
| ES2384036T3 (es) | 2012-06-28 |
| RU2009138039A (ru) | 2011-04-20 |
| ZA200906573B (en) | 2011-11-30 |
| WO2008112900A1 (en) | 2008-09-18 |
| CN103214473A (zh) | 2013-07-24 |
| CN101641350A (zh) | 2010-02-03 |
| KR20090119999A (ko) | 2009-11-23 |
| TW200904449A (en) | 2009-02-01 |
| MX2009009535A (es) | 2009-09-16 |
| US20080255088A1 (en) | 2008-10-16 |
| IL200250A0 (en) | 2010-04-29 |
| IL200250A (en) | 2014-12-31 |
| US20120178738A1 (en) | 2012-07-12 |
| JP5421787B2 (ja) | 2014-02-19 |
| BRPI0808828A2 (pt) | 2017-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA35285B1 (fr) | Indazoles | |
| NO20090166L (no) | Amino-imidazoloner og deres anvendelse som et medikament for behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerering og demens | |
| CY1119326T1 (el) | Φαινυλο-3-αζα-δικυκλο[3.1.0]εξ-3-υλο-μεθανονες και η χρηση αυτων ως φαρμακο | |
| UA106692C2 (uk) | ІМІДАЗО[5,1-f][1,2,4]ТРИАЗИНИ ДЛЯ ЛІКУВАННЯ НЕВРОЛОГІЧНИХ РОЗЛАДІВ | |
| ZA200906573B (en) | Dibenzo[1,4]oxazapine compounds | |
| TW201129562A (en) | Iminothiadiazine dioxide compounds as BACE inhibitors, compositions, and their use | |
| MX2010007683A (es) | Derivados heterociclicos fusionados y metodos de uso como inhibidores de c-met. | |
| NO20090755L (no) | Amino-imidazoloner og deres anvendelse som et medikament for behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerering og demens | |
| MY167135A (en) | Fused heterocyclic derivatives and methods of use | |
| MX2009011830A (es) | Compuestos amino-heterociclicos. | |
| MX2012007273A (es) | Pteridinonas como inhibidores de la quinasa tipo polo. | |
| CY1117830T1 (el) | Υποκατεστημενα παραγωγα τρικυκλικων οξεων ως αγωνιστες του υποδοχεα s1p1 χρησιμα στην αγωγη αυτοανοσων και φλεγμονοδων διαταραχων | |
| MX2009013885A (es) | Derivados de quinolina fusionados utiles como moduladores de acido gamma-aminobutirico. | |
| MX2010001486A (es) | Derivados de tetrahidropiridin carboxamida como antagonistas de trpvl. | |
| NO20084516L (no) | Terfenylderivater for behandling av alzheimers sykdom | |
| MA33407B1 (fr) | Composes bicycliques et tricycliques servant d'inhibiteurs de kat ii | |
| MX350862B (es) | Acidos de piperidinil naftilacetico. | |
| TW200735878A (en) | Pharmaceutical compositions | |
| MX2009010727A (es) | Heterociclos como antagonistas de orexina. | |
| UA86873C2 (en) | SUBSTITUTED ARYL 1,4-PYRAZlNE DERIVATIVES | |
| NZ593279A (en) | Aroylamino - and heteroaroylamino-substituted piperidines as glyt-1 inhibitors | |
| DE602006007483D1 (de) | ||
| ATE407126T1 (de) | Herstellung von (s)-4-fluormethyl-dihydro-furan-2-on | |
| EA200870492A1 (ru) | N-оксиды производных пиридилметилпиперазина и - пиперидина | |
| BRPI0606730A2 (pt) | derivados de fenil metanona 2,5-di-substituìdos como inibidores do transportador de glicina 1 (glyt-1) para o tratamento de distúbios neurológicos e neuropsiquiátricos |